David C. Hastings - 14 Feb 2025 Form 4 Insider Report for Arbutus Biopharma Corp (ABUS)

Reporting relationship: Chief Financial Officer
Issuer ticker: ABUS
Reported as of: 14 Feb 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 19 Feb 2025, 18:25:30 UTC
Prior SEC filing: 05 Feb 2025
Next SEC filing: 30 Jun 2025
Source filing: View source filing
Reporting owner signature: /s/ David C. Hastings

Key filing fact

David C. Hastings filed Form 4 for Arbutus Biopharma Corp (ABUS) on 19 Feb 2025.

Key facts

This page summarizes David C. Hastings's Form 4 filing for Arbutus Biopharma Corp (ABUS).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 19 Feb 2025, 18:25.

Change

Previous filing in this sequence was filed on 05 Feb 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ABUS transaction

Common Shares

Award

Transaction value: $0
Shares: +90,100
Change %: +56%
Price: $0.000000
Shares after: 249,824
Date: 14 Feb 2025
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ABUS transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +365,800
Change %
Price: $0.000000
Shares after: 365,800
Date: 14 Feb 2025
Ownership: Direct
Underlying class: Common Shares
Underlying amount: 365,800
Exercise price: $3.29
Footnotes: F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Represents the grant of restricted stock units ("RSUs"), which represent a contingent right to receive one common share for each RSU. The RSUs vest in three equal annual installments beginning one year from the grant date, subject to the Reporting Person's continuous service as of each vesting date. Unless otherwise provided, on each vesting date, common shares will automatically be sold to satisfy the Reporting Person's tax withholding obligations in a non-discretionary transaction.

Footnote F2

Reflects the closing price of the Company's common shares on the Nasdaq Stock Market on the date of the grant.

Footnote F3

This option vests over a four-year period, with 1/48th of the shares subject to the option vesting in substantially equal monthly installments measured from one month following the grant date, subject to the Reporting Person's continuous service as of each vesting date.